2026 Pharma CX Marketing Summit

For decades, HCP engagement has meant segmenting physicians into broad buckets — specialty, tier, prescribing volume — and hoping the message lands. AI is breaking that model. Today's HCPs expect experiences shaped by their actual behavior, preferences, and moment-in-time needs, not a persona built from last year's data. But personalization at scale raises hard questions pharma marketers can't ignore: How much precision is genuinely useful versus invasive? Where does AI-driven relevance end and algorithmic guesswork begin? And what does trust look like when the HCP knows they're being read by a machine? This panel brings together CX and digital leaders reimagining the HCP journey from the ground up — exploring what it actually takes to move from segmentation to true individualization, and what pharma stands to gain (or risk) in getting there first.

The traditional marketing funnel assumes a patient moves neatly from awareness to consideration to action. That assumption no longer holds. Today's patients bounce between search, social, symptom-checkers, AI chatbots, caregiver forums, and their HCP — often in a different order every time, and rarely in a straight line. This panel explores what happens when journey mapping stops trying to force patients into a linear path and instead reflects how people actually move: nonlinear, recursive, and driven as much by moments of doubt as moments of intent. In this session, participants share how they are rethinking journey design for a post-linear reality — what gets built differently, what gets measured differently, and what pharma marketers need to unlearn about the funnel model that's shaped the industry for decades.

AI has made precision targeting more powerful than ever — pharma brands can now identify, segment, and personalize outreach to patients and HCPs with a level of granularity that was unimaginable a few years ago. But that same precision is raising uncomfortable questions the industry can no longer sidestep: How much personal data is too much? Where's the line between relevant and invasive? And who's accountable when a "personalized" experience feels like surveillance? This panel brings together voices from brand, compliance, and data strategy to debate the tension at the heart of modern pharma CX — the pressure to deliver hyper-relevant experiences versus the responsibility to protect patient trust and privacy. Expect real disagreement, not a tidy consensus: panelists will challenge each other on where the industry should draw the line, and what happens to brands that get it wrong.